Back To Search Instructions
Protocols
10 protocols meet the specified criteria
Disease Site: Myeloid and Monocytic Leukemia
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
1100000610A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications (10-CBA)Open
1607716638A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid LeukemiaOpen
1609875338A Phase 1 Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous PF-06747143, Administered as Single Agent or in Combination with Standard Chemotherapy in Adult Patients with Acute Myeloid LeukemiaOpen
1609876907A Phase I/II Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or BendamustineOpen
1701114637Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease RegistryOpen
1704374063A Phase 1 Open-Label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer SubjectsOpen
1705421711A Phase I/II, Open-label, 2 Arm Study to Investigate the Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of GSK2879552 Administered Alone or in Combination With Azacitidine, in Adult Subjects With IPSS-R High and Very High Risk Myelodysplastic Syndromes (MDS) Previously Treated With Hypomethylating Agents (HMA)Open
1705461569Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)Open
SGN33A-005A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) versus Placebo in Combination with Azacitidine or Decitabine in the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)Not Open